Plaque psoriasis is the most common type of psoriasis. Plaques are pink/red, raised, thick, inflamed skin patches covered by silvery-white scales. They typically have well-defined edges and may itch.

Getting a plaque psoriasis diagnosis is straightforward. Your healthcare provider takes your medical history and inquires about symptoms and overall health. They may also want to know if you’re under ...

Icotrokinra is an investigational oral peptide that blocks interleukin (IL)-23 receptor, which plays a significant role in ...

Medically reviewed by Leah Ansell, MDMedically reviewed by Leah Ansell, MD Plaque psoriasis is the most common ... body but ...

Recent Phase 3 trial results for Icotrokinra (JNJ-2113), an investigational oral peptide from Johnson & Johnson, have shown the drug’s potential to offer significant relief for patients suffering from ...

Icotrokinra, formerly known as JNJ-2113, is an investigational oral peptide that blocks the interleukin (IL)-23 receptor, which plays a significant role in the pathogenesis of moderate to severe ...

In people with psoriasis, immune cells secrete inflammatory biomarkers that cause the skin to overproduce keratinocytes and create plaques on the skin that are characteristic of plaque psoriasis, ...

scalp, and groin, but it can also be in the underarms, on your nails, or under the breasts. It can be anywhere.” And beyond the physical symptoms, plaque psoriasis also frequently has negative ...

Researchers conducted a retrospective study to investigate the effectiveness of brodalumab for treating difficult-to-manage ...

Positive, phase 3 data for once-daily JNJ-2113 (icotrokinra) has been announced by Protagonist Therapeutics in collaboration with Johnson & Johnson that demonstrated "significant" skin clearance ...

The study was conducted among patients with plaque psoriasis affecting special areas such as the scalp, genitals and/or hands ...